

Filed on behalf of Petitioner COALITION FOR AFFORDABLE DRUGS X LLC

By: Jeffrey D. Blake, Esq.
MERCHANT & GOULD P.C.
191 Peachtree Street N.E., Suite 4300
Atlanta, GA 30303
jblake@merchantgould.com
Main Telephone: (404) 954-5100
Main Facsimile: (404) 954-5099

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS X LLC,
Petitioner,

v.

ANACOR PHARMACEUTICALS, INC.,
Patent Owner.

Case IPR2015-01776 (Patent 7,582,621 B2)

**DECLARATION OF S. NARASIMHA MURTHY PH.D. IN SUPPORT OF
PETITIONER'S REPLY TO PATENT OWNER'S RESPONSE**

TABLE OF CONTENTS

I. INTRODUCTION	4
II. BACKGROUND AND EXPERIENCE	5
III. COMPENSATION AND RELATIONSHIP TO THE PARTIES	8
IV. MATERIALS CONSIDERED	9
V. LEGAL STANDARDS	13
A. Legal Principles of Claim Construction	13
B. Legal Principles of Obviousness	13
C. Level of Ordinary Skill in the Art	14
VI. THE '621 PATENT	15
A. The '060 Provisional	16
B. The '621 Patent	20
VII. THE PRIOR ART	20
A. <i>Austin</i>	20
B. <i>Brehove</i>	26
C. <i>Freeman</i>	33
VIII. A POSITA WOULD REASONABLY EXPECT A LOW MOLECULAR WEIGHT COMPOUND TO SUCCESSFULLY PENETRATE THE NAIL PLATE	38

IX. A POSITA WOULD HAVE A REASONABLE EXPECTATION OF SUCCESSFULLY TREATING ONYCHOMYCOSIS BASED ON THE POTENCY OF TAVABOROLE AGAINST *CANDIDA ALBICANS* DISCLOSED BY AUSTIN53

X. A POSITA WOULD HAVE REASON TO COMBINE *AUSTIN* AND *BREHOVE* OR *FREEMAN* TO ARRIVE AT A REASONABLE EXPECTATION OF SUCCESSFULLY TREATING ONYCHOMYCOSIS WITH TAVABOROLE62

XI. CONCLUSION64

I, S. Narasimha Murthy, Ph.D., hereby state the following:

I. INTRODUCTION

1. I provide this declaration in support of Petitioner's Reply to Patent Owner's Response in the *Inter Partes* Review of U.S. Patent No. 7,582,621 (hereinafter, "the '621 Patent").

2. I previously provided a declaration dated June 15, 2015, in support of the petition filed by Coalition for Affordable Drugs X LLC. My previous declaration is Ex. 1008 and is incorporated herein by reference.

3. I am competent to make this declaration based upon my personal knowledge and technical expertise, which I addressed in my first declaration, dated June 15, 2015.

4. As was the case for my original declaration, this declaration was drafted with the help of attorneys. As I explained during my deposition, the drafting process involved my review of the patents and the literature and several initial teleconferences with attorneys, during which I discussed the technology and explained my opinions. (*See* Ex. 2032, at 474:17 – 475:22.) Following these teleconferences, the attorneys compiled my opinions into a draft declaration for my review, revision and comment. (*See id.* at 475:22 – 476:9.) I worked together with the attorneys to review and revise multiple drafts to ensure that all of my

recommendations and opinions were incorporated into both my original declaration (*see id.*) and this declaration.

5. This Declaration is based on information currently available to me. I reserve the right to continue my investigation and analysis, which may include a review of documents and information not yet produced. I further reserve the right to expand or otherwise modify my opinions and conclusions as my investigation and study continues, and to supplement my opinions and conclusions in response to any additional information that becomes available to me.

II. BACKGROUND AND EXPERIENCE

6. I received a Bachelor of Pharmacy from Bangalore University, India, in 1992, a Master of Pharmacy from Bangalore University, India, in 1994, and a Ph.D. in Pharmaceutics from Bangalore University, India, in 2002. I completed my postdoctoral research in the department of Molecular and Cellular Biophysics at Roswell Park Cancer Institute, Buffalo, NY from 2002-2005.

7. I was an Assistant Professor of Pharmaceutics at the M.S.R. College of Pharmacy, India from 1994-2002. I was an Assistant Professor of Pharmaceutics at Ohio Northern University, Ohio from 2005-2006, and an Assistant Professor of Pharmaceutics at the University of Mississippi from 2006-2011. I have been an Associate Professor of Pharmaceutics at the University of Mississippi from 2011

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.